TaiwanJ Pharmaceuticals Co., Ltd. (TPEX:6549)
Taiwan · Delayed Price · Currency is TWD 6.78
-0.10 (-1.45%)
Sep 11, 2026, 2:05 PM CST
TaiwanJ Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | 22.74 | 15.36 | 22.06 | |
Revenue Growth | - | - | - | 48.11% | -30.38% | - |
Cost of Revenue | - | - | - | - | 75.28 | - |
Gross Profit | - | - | - | 22.74 | -59.92 | 22.06 |
Selling, General & Admin | 14.68 | 14.51 | 15.64 | 15.38 | 12.98 | 14.05 |
Research & Development | 9.68 | 10.7 | 11.31 | 13.97 | 12.74 | 17.73 |
Operating Expenses | 21.29 | 25.21 | 26.96 | 29.35 | 36.47 | 31.78 |
Operating Income | -21.29 | -25.21 | -26.96 | -6.61 | -96.39 | -9.73 |
Interest Expense | -0.07 | -0.05 | -0.01 | -0.02 | -0.01 | -0.01 |
Interest & Investment Income | 1.44 | 1.64 | 2.1 | 2.52 | 0.49 | 0.04 |
Currency Exchange Gain (Loss) | 1.57 | -0.72 | 2.53 | 0.33 | 3.29 | -0.62 |
Other Non Operating Income (Expenses) | - | 0.01 | - | 0.01 | 0.16 | - |
EBT Excluding Unusual Items | -18.35 | -24.34 | -22.34 | -3.77 | -92.47 | -10.32 |
Pretax Income | -18.35 | -24.34 | -22.34 | -3.77 | -92.47 | -10.32 |
Income Tax Expense | - | - | - | 2.27 | - | 2.11 |
Net Income | -18.35 | -24.34 | -22.34 | -6.05 | -92.47 | -12.42 |
Net Income to Common | -18.35 | -24.34 | -22.34 | -6.05 | -92.47 | -12.42 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 80 | 80 | 77 | 75 | 75 | 75 |
Shares Outstanding (Diluted) | 80 | 80 | 77 | 75 | 75 | 75 |
Shares Change | 1.36% | 4.68% | 1.89% | - | 0.03% | 6.07% |
EPS (Basic) | -0.23 | -0.30 | -0.29 | -0.08 | -1.23 | -0.17 |
EPS (Diluted) | -0.23 | -0.30 | -0.29 | -0.08 | -1.23 | -0.17 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -19.47 | -24.46 | -22.62 | -2.26 | -22.3 | -10.05 |
Free Cash Flow Per Share | -0.24 | -0.30 | -0.30 | -0.03 | -0.30 | -0.13 |
Gross Margin | - | - | - | 100.00% | - | 100.00% |
Operating Margin | - | - | - | -29.07% | -627.77% | -44.09% |
Profit Margin | - | - | - | -26.59% | -602.20% | -56.32% |
Free Cash Flow Margin | - | - | - | -9.95% | -145.22% | -45.56% |
EBITDA | -20.71 | -24.37 | -25.76 | -5.29 | -20.49 | -9.12 |
EBITDA Margin | - | - | - | -23.28% | -133.41% | -41.37% |
D&A For EBITDA | 0.59 | 0.84 | 1.19 | 1.32 | 75.91 | 0.6 |
EBIT | -21.29 | -25.21 | -26.96 | -6.61 | -96.39 | -9.73 |
EBIT Margin | - | - | - | -29.07% | - | -44.09% |